Neovascular age-related macular degeneration and anti-VEGF nonresponders

References

• West SK. Looking forward to 20/20: a focus on the epidemiology of eye diseases. Epidemiol. Rev.22(1), 64–70 (2000).
   PubMed Web of Science ®Google Scholar
• Lee PP, Feldman ZW, Ostermann J, Brown DS, Sloan FA. Longitudinal prevalence of major eye diseases. Arch. Ophthalmol.121(9), 1303–1310 (2003).
   PubMedGoogle Scholar
• Ferris FL 3rd, Fine SL, Hyman L. Age-related macular degeneration and blindness due to neovascular maculopathy. Arch. Ophthalmol.102(11), 1640–1642 (1984).
   PubMed Web of Science ®Google Scholar
• Ferrara N, Gerber HP, Lecouter J. The biology of VEGF and its receptors. Nat. Med.9(6), 669–676 (2003).
   PubMed Web of Science ®Google Scholar
• Kliffen M, Sharma HS, Mooy CM, Kerkvliet S, De Jong PT. Increased expression of angiogenic growth factors in age-related maculopathy. Br. J. Ophthalmol.81(2), 154–162 (1997).
   PubMed Web of Science ®Google Scholar
• Brown DM, Kaiser PK, Michels M et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N. Engl. J. Med.355(14), 1432–1444 (2006).
   PubMed Web of Science ®Google Scholar
• Rosenfeld PJ, Brown DM, Heier JS et al. Ranibizumab for neovascular age-related macular degeneration. N. Engl. J. Med.355(14), 1419–1431 (2006).
   PubMed Web of Science ®Google Scholar
• Macular Photocoagulation Study Group. Argon laser photocoagulation for senile macular degeneration. Results of a randomized clinical trial. Arch. Ophthalmol.100(6), 912–918 (1982).
   PubMed Web of Science ®Google Scholar
• Bressler NM. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two-year results of 2 randomized clinical trials-tap report 2. Arch. Ophthalmol.119(2), 198–207 (2001).
   PubMed Web of Science ®Google Scholar
• Gragoudas ES, Adamis AP, Cunningham ET Jr, Feinsod M, Guyer DR. Pegaptanib for neovascular age-related macular degeneration. N. Engl. J. Med.351(27), 2805–2816 (2004).
   PubMed Web of Science ®Google Scholar
• Carmeliet P, Ferreira V, Breier G et al. Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele. Nature380(6573), 435–439 (1996).
   PubMed Web of Science ®Google Scholar
• Ferrara N, Carver-Moore K, Chen H et al. Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene. Nature380(6573), 439–442 (1996).
   PubMed Web of Science ®Google Scholar
• Ivan M, Kondo K, Yang H et al. Hifa targeted for vhl-mediated destruction by proline hydroxylation: implications for O2 sensing. Science292(5516), 464–468 (2001).
   PubMed Web of Science ®Google Scholar
• Jaakkola P, Mole DR, Tian YM et al. Targeting of HIF-a to the von Hippel–Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation. Science292(5516), 468–472 (2001).
   PubMed Web of Science ®Google Scholar
• Dvorak HF. Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. J. Clin. Oncol.20(21), 4368–4380 (2002).
   PubMed Web of Science ®Google Scholar
• Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell86(3), 353–364 (1996).
   PubMed Web of Science ®Google Scholar
• Luo JC, Yamaguchi S, Shinkai A, Shitara K, Shibuya M. Significant expression of vascular endothelial growth factor/vascular permeability factor in mouse ascites tumors. Cancer Res.58(12), 2652–2660 (1998).
   PubMed Web of Science ®Google Scholar
• Hurwitz H, Fehrenbacher L, Novotny W et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N. Engl. J. Med.350(23), 2335–2342 (2004).
   PubMed Web of Science ®Google Scholar
• Nozaki M, Raisler BJ, Sakurai E et al. Drusen complement components c3a and c5a promote choroidal neovascularization. Proc. Natl Acad. Sci. USA103(7), 2328–2333 (2006).
   PubMed Web of Science ®Google Scholar
• Kvanta A, Algvere PV, Berglin L, Seregard S. Subfoveal fibrovascular membranes in age-related macular degeneration express vascular endothelial growth factor. Invest. Ophthalmol. Vis. Sci.37(9), 1929–1934 (1996).
   PubMed Web of Science ®Google Scholar
• Dipietro LA. Thrombospondin as a regulator of angiogenesis. EXS79, 295–314 (1997).
   PubMedGoogle Scholar
• Watanabe K, Hasegawa Y, Yamashita H et al. Vasohibin as an endothelium-derived negative feedback regulator of angiogenesis. J. Clin. Invest.114(7), 898–907 (2004).
   PubMed Web of Science ®Google Scholar
• Nowak JZ. Age-related macular degeneration (AMD): pathogenesis and therapy. Pharmacol. Rep.58(3), 353–363 (2006).
   PubMed Web of Science ®Google Scholar
• Mori K, Duh E, Gehlbach P et al. Pigment epithelium-derived factor inhibits retinal and choroidal neovascularization. J. Cell Physiol.188(2), 253–263 (2001).
   PubMed Web of Science ®Google Scholar
• Zhang SX, Wang JJ, Gao G, Shao C, Mott R, Ma JX. Pigment epithelium-derived factor (PEDF) is an endogenous antiinflammatory factor. FASEB J.20(2), 323–325 (2006).
   PubMed Web of Science ®Google Scholar
• Tong JP, Chan WM, Liu DT et al. Aqueous humor levels of vascular endothelial growth factor and pigment epithelium-derived factor in polypoidal choroidal vasculopathy and choroidal neovascularization. Am. J. Ophthalmol.141(3), 456–462 (2006).
   PubMed Web of Science ®Google Scholar
• Ogata N, Matsuoka M, Imaizumi M, Arichi M, Matsumura M. Decrease of pigment epithelium-derived factor in aqueous humor with increasing age. Am. J. Ophthalmol.137(5), 935–936 (2004).
   PubMedGoogle Scholar
• Zarbin MA. Current concepts in the pathogenesis of age-related macular degeneration. Arch. Ophthalmol.122(4), 598–614 (2004).
   PubMed Web of Science ®Google Scholar
• Rakic JM, Lambert V, Devy L et al. Placental growth factor, a member of the VEGF family, contributes to the development of choroidal neovascularization. Invest. Ophthalmol. Vis. Sci.44(7), 3186–3193 (2003).
   PubMed Web of Science ®Google Scholar
• Avery RL, Pieramici DJ, Rabena MD, Castellarin AA, Nasir MA, Giust MJ. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Ophthalmology113(3), 363–372.e5 (2006).
   PubMed Web of Science ®Google Scholar
• Geitzenauer W, Michels S, Prager F et al. Early effects of systemic and intravitreal bevacizumab (Avastin) therapy for neovascular age-related macular degeneration. Klin. Monatsbl. Augenheilkd.223(10), 822–827 (2006).
   PubMed Web of Science ®Google Scholar
• Lazic R, Gabric N. Intravitreally administered bevacizumab (Avastin) in minimally classic and occult choroidal neovascularization secondary to age-related macular degeneration. Graefes Arch. Clin. Exp. Ophthalmol.245(1), 68–73 (2007).
   PubMed Web of Science ®Google Scholar
• Moshfeghi AA, Rosenfeld PJ, Puliafito CA et al. Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration: twenty-four-week results of an uncontrolled open-label clinical study. Ophthalmology113(11), 2002.e1–2002.e12 (2006).
   Google Scholar
• Yoganathan P, Deramo VA, Lai JC, Tibrewala RK, Fastenberg DM. Visual improvement following intravitreal bevacizumab (Avastin) in exudative age-related macular degeneration. Retina26(9), 994–998 (2006).
   PubMed Web of Science ®Google Scholar
• Lux A, Llacer H, Heussen FM, Joussen AM. Non-responders to bevacizumab (Avastin) therapy of choroidal neovascular lesions. Br. J. Ophthalmol.91(10), 1318–1322 (2007).
   PubMed Web of Science ®Google Scholar
• Lee S, Chen TT, Barber CL et al. Autocrine VEGF signaling is required for vascular homeostasis. Cell130(4), 691–703 (2007).
   PubMed Web of Science ®Google Scholar
• Yu JL, Rak JW, Coomber BL, Hicklin DJ, Kerbel RS. Effect of p53 status on tumor response to antiangiogenic therapy. Science295(5559), 1526–1528 (2002).
   PubMed Web of Science ®Google Scholar
• Glade Bender J, Cooney EM, Kandel JJ, Yamashiro DJ. Vascular remodeling and clinical resistance to antiangiogenic cancer therapy. Drug Resist. Update7(4–5), 289–300 (2004).
   PubMedGoogle Scholar
• Cho CH, Kim KE, Byun J et al. Long-term and sustained COMP-Ang1 induces long-lasting vascular enlargement and enhanced blood flow. Circ. Res.97(1), 86–94 (2005).
   PubMed Web of Science ®Google Scholar
• Uemura A, Ogawa M, Hirashima M et al. Recombinant angiopoietin-1 restores higher-order architecture of growing blood vessels in mice in the absence of mural cells. J. Clin. Invest.110(11), 1619–1628 (2002).
   PubMed Web of Science ®Google Scholar
• Alitalo K, Tammela T, Petrova TV. Lymphangiogenesis in development and human disease. Nature438(7070), 946–953 (2005).
   PubMed Web of Science ®Google Scholar
• Ikeda Y, Yonemitsu Y, Onimaru M et al. The regulation of vascular endothelial growth factors (VEGF-A, -C, and -D) expression in the retinal pigment epithelium. Exp. Eye Res.83(5), 1031–1040 (2006).
   PubMed Web of Science ®Google Scholar
• Witmer AN, Van Blijswijk BC, Dai J et al. VEGFR-3 in adult angiogenesis. J. Pathol.195(4), 490–497 (2001).
   PubMed Web of Science ®Google Scholar
• Schaal S, Kaplan HJ, Tezel TH. Is there tachyphylaxis to intravitreal anti-vascular endothelial growth factor pharmacotherapy in age-related macular degeneration? Ophthalmology115(12), 2199–2205 (2008).
   PubMed Web of Science ®Google Scholar
• Hlushchuk R, Baum O, Gruber G, Wood J, Djonov V. The synergistic action of a VEGF-receptor tyrosine-kinase inhibitor and a sensitizing PDGF-receptor blocker depends upon the stage of vascular maturation. Microcirculation14(8), 813–825 (2007).
   PubMed Web of Science ®Google Scholar
• Forooghian F, Cukras C, Meyerle CB, Chew EY, Wong WT. Tachyphylaxis after intravitreal bevacizumab for exudative age-related macular degeneration. Retina29(6), 723–731 (2009).
   PubMed Web of Science ®Google Scholar
• Espinosa-Heidmann DG, Suner IJ, Hernandez EP, Monroy D, Csaky KG, Cousins SW. Macrophage depletion diminishes lesion size and severity in experimental choroidal neovascularization. Invest. Ophthalmol. Vis. Sci.44(8), 3586–3592 (2003).
   PubMed Web of Science ®Google Scholar
• Grossniklaus HE, Ling JX, Wallace TM et al. Macrophage and retinal pigment epithelium expression of angiogenic cytokines in choroidal neovascularization. Mol. Vis.8, 119–126 (2002).
   PubMed Web of Science ®Google Scholar
• Sakurai E, Anand A, Ambati BK, van Rooijen N, Ambati J. Macrophage depletion inhibits experimental choroidal neovascularization. Invest. Ophthalmol. Vis. Sci.44(8), 3578–3585 (2003).
   PubMed Web of Science ®Google Scholar
• Tatar O, Yoeruek E, Szurman P et al. Effect of bevacizumab on inflammation and proliferation in human choroidal neovascularization. Arch. Ophthalmol.126(6), 782–790 (2008).
   PubMed Web of Science ®Google Scholar
• Lafaut BA, Aisenbrey S, van Den Broecke C, Bartz-Schmidt KU, Heimann K. Polypoidal choroidal vasculopathy pattern in age-related macular degeneration: a clinicopathologic correlation. Retina20(6), 650–654 (2000).
   PubMedGoogle Scholar
• Ciardella AP, Donsoff IM, Huang SJ, Costa DL, Yannuzzi LA. Polypoidal choroidal vasculopathy. Surv. Ophthalmol.49(1), 25–37 (2004).
   PubMed Web of Science ®Google Scholar
• Cho M, Barbazetto IA, Freund KB. Refractory neovascular age-related macular degeneration secondary to polypoidal choroidal vasculopathy. Am. J. Ophthalmol.148(1), 70.e1–78.e1 (2009).
   Google Scholar
• Gerhardt H, Betsholtz C. Endothelial–pericyte interactions in angiogenesis. Cell Tissue Res.314(1), 15–23 (2003).
   PubMed Web of Science ®Google Scholar
• Hirschi KK, Rohovsky SA, D’Amore PA. PDGF, TGF-β, and heterotypic cell–cell interactions mediate endothelial cell-induced recruitment of 10T1/2 cells and their differentiation to a smooth muscle fate. J. Cell Biol.141(3), 805–814 (1998).
   PubMed Web of Science ®Google Scholar
• Sims DE. Diversity within pericytes. Clin. Exp. Pharmacol. Physiol.27(10), 842–846 (2000).
   PubMed Web of Science ®Google Scholar
• Holash J, Wiegand SJ, Yancopoulos GD. New model of tumor angiogenesis: dynamic balance between vessel regression and growth mediated by angiopoietins and VEGF. Oncogene18(38), 5356–5362 (1999).
   PubMed Web of Science ®Google Scholar
• Brown DM, Regillo CD. Anti-VEGF agents in the treatment of neovascular age-related macular degeneration: applying clinical trial results to the treatment of everyday patients. Am. J. Ophthalmol.144(4), 627–637 (2007).
   PubMed Web of Science ®Google Scholar
• Fung AE, Lalwani GA, Rosenfeld PJ et al. An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration. Am. J. Ophthalmol.143(4), 566–583 (2007).
   PubMed Web of Science ®Google Scholar
• Shah GK, Sang DN, Hughes MS. Verteporfin combination regimens in the treatment of neovascular age-related macular degeneration. Retina29(2), 133–148 (2009).
   PubMedGoogle Scholar
• Augustin AJ, Puls S, Offermann I. Triple therapy for choroidal neovascularization due to age-related macular degeneration: verteporfin PDT, bevacizumab, and dexamethasone. Retina27(2), 133–140 (2007).
   PubMed Web of Science ®Google Scholar